Welcome!

News Feed Item

UK Injectables Market Outlook to 2017

NEW YORK, Feb. 17, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

UK Injectables Market Outlook to 2017
http://www.reportlinker.com/p01622848/UK-Injectables-Market-Outlook-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Injectables occupy a considerable prominence in UK irrespective of diminishing growth in the pharmaceutical market for 2-3 years. The advancements in technology up-gradation and investments have provided immense growth opportunities for injectables to emerge in the UK's pharmaceutical industry in recent years. According to RNCOS' research report, "UK Injectables Market Outlook to 2017", the market is anticipated to grow at a CAGR of approximately 4.5% during 2012-2017. The increasing need of injectables for diseases like diabetes, infectious diseases and arthritis is primarily driving this market.

The said report is a study of the UK injectable market in terms of major therapeutic areas. It covers the historical sales trend of injectables for categories such as Diabetes, Vaccines, Sex Hormones & Antagonist in Malign Disease, Anticoagulants & Protamine, Hypothalamic & Pituitary Hormones, Rheumatic Diseases & Gout, etc. Not only this, the report also provides the sales trend of the top 10 injectable drugs in the UK market along with a rational analysis.

Certain pharmaceutical firms in UK's injectable market have established their foothold given the diverse and innovative product offerings. Several small pharma majors too have been aggressively competing with big pharmaceutical players in order to establish themselves in the market. The report highlights a detailed comparison of the market shares of different players in the injectables market.

The study provides an insight about the competitive landscape, which includes business profiling and a strength-weakness analysis of top pharmaceutical players in the UK injectable business. There's also a coverage of the detailed analysis of their top injectable drugs in terms of revenue.

A lot of investment is being done in research and development of injectables in order to improve their medical outcomes. Here it is worth mentioning that even the country's government has significantly contributed towards the development of innovative medicines.

Moreover, the Government has shifted its focus towards cost effective drug treatments by fixing up the drug prices as per their clinical value. In addition, there are a set of regulations that support the injectable drug business in the country. In this context, various regulatory processes such as drug licensing, marketing/ promotion, pricing etc. have been comprehensively covered in the report. In a nutshell, the report covers every aspect of UK injectables which will help the industry players to take strategic decisions.

1. Analyst View

2. Research Methodology

3. UK Injectables Market Outlook to 2017
3.1 Current and Future Market Analysis
3.1.1 By Top 10 Injectables
3.1.2 By Top 10 Therapeutics
3.1.3 By Major Players

4. Drivers and Challenges
4.1 Drivers
4.2 Challenges

5. Regulatory Environment

6. Competitive Landscape
6.1 Novo Nordisk
6.1.1 Business Overview
6.1.2 Key Injectable Sales
6.1.3 Strengths and Weaknesses
6.1.4 Recent Developments
6.2 Sanofi
6.2.1 Business Overview
6.2.2 Key Injectable Sales
6.2.3 Strengths and Weaknesses
6.2.4 Recent Developments
6.3 Eli Lily & Co.
6.3.1 Business Overview
6.3.2 Key Injectable Sales
6.3.3 Strengths and Weaknesses
6.4 Pfizer
6.4.1 Business Overview
6.4.2 Key Injectable Sales
6.4.3 Strengths and Weaknesses
6.4.4 Recent Developments
6.5 Abbott Laboratories
6.5.1 Business Overview
6.5.2 Key Injectable Sales
6.5.3 Strengths and Weaknesses
6.5.4 Recent Developments
6.6 Takeda Pharmaceutical Company Ltd
6.6.1 Business Overview
6.6.2 Key Injectable Sales
6.6.3 Strengths and Weaknesses
6.6.4 Recent Developments

List of Figures:

Figure 3-1: Injectables Market (Million £), 2012-2017
Figure 3-2: Injectables Market by Player (%), 2010
Figure 3-3: Injectables Market by Player (%), 2012
Figure 6-1: Novo Nordisk - Break up of Revenue by Business Segment (%), 2012
Figure 6-2: Novo Nordisk - Diabetes Care Revenue by Segment (%), 2012
Figure 6-3: Novo Nordisk UK - Break up of Revenue by Segment (%), 2012
Figure 6-4: Sanofi - Break up of Revenue by Business Segment (%), 2012
Figure 6-5: Eli Lily & Co. - Break up of Revenue by Business Segment (%), 2012
Figure 6-6: Eli Lily & Co. - Human Pharmaceutical Division Revenue by Segment (%), 2012
Figure 6-7: Pfizer - Break up of Revenue by Business Segment (%), 2012

List of Tables:

Table 3-1: Top 10 Injectable Sales (Million £), 2010-2012
Table 3-2: Injectable Sales by Top 10 Therapeutics (Million £), 2010-2012
Table 6-1: Novo Nordisk UK - Key Injectable Sales (Million £), 2010-2012
Table 6-2: Novo Nordisk UK - Strengths and Weaknesses
Table 6-3: Sanofi UK - Key Injectable Sales (Million £), 2010-2012
Table 6-4: Sanofi UK - Strengths and Weaknesses
Table 6-5: Eli Lily & Co. UK - Key Injectable Sales (Million £), 2010-2012
Table 6-6: Eli Lily & Co. UK - Strengths and Weaknesses
Table 6-7: Pfizer UK - Key Injectable Sales (Million £), 2010-2012
Table 6-8: Pfizer UK - Strengths and Weaknesses
Table 6-9: Abbott Laboratories UK - Key Injectable Sales (Million £), 2010-2012
Table 6-10: Abbott Laboratories UK - Strengths and Weaknesses
Table 6-11: Takeda Pharmaceuticals UK - Key Injectable Sales (Million £), 2010-2012
Table 6-12: Takeda Pharmaceuticals UK - Strengths and Weaknesses

To order this report: UK Injectables Market Outlook to 2017
http://www.reportlinker.com/p01622848/UK-Injectables-Market-Outlook-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Yuasa System will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Yuasa System is introducing a multi-purpose endurance testing system for flexible displays, OLED devices, flexible substrates, flat cables, and films in smartphones, wearables, automobiles, and healthcare.
The session is centered around the tracing of systems on cloud using technologies like ebpf. The goal is to talk about what this technology is all about and what purpose it serves. In his session at 21st Cloud Expo, Shashank Jain, Development Architect at SAP, will touch upon concepts of observability in the cloud and also some of the challenges we have. Generally most cloud-based monitoring tools capture details at a very granular level. To troubleshoot problems this might not be good enough.
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
Organizations do not need a Big Data strategy; they need a business strategy that incorporates Big Data. Most organizations lack a road map for using Big Data to optimize key business processes, deliver a differentiated customer experience, or uncover new business opportunities. They do not understand what’s possible with respect to integrating Big Data into the business model.
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busine...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities – ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups. As a result, many firms employ new business models that place enormous impor...
SYS-CON Events announced today that Taica will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Taica manufacturers Alpha-GEL brand silicone components and materials, which maintain outstanding performance over a wide temperature range -40C to +200C. For more information, visit http://www.taica.co.jp/english/.
SYS-CON Events announced today that Dasher Technologies will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Dasher Technologies, Inc. ® is a premier IT solution provider that delivers expert technical resources along with trusted account executives to architect and deliver complete IT solutions and services to help our clients execute their goals, plans and objectives. Since 1999, we'v...
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, will discuss how they b...
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...
SYS-CON Events announced today that MIRAI Inc. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MIRAI Inc. are IT consultants from the public sector whose mission is to solve social issues by technology and innovation and to create a meaningful future for people.
SYS-CON Events announced today that TidalScale, a leading provider of systems and services, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale has been involved in shaping the computing landscape. They've designed, developed and deployed some of the most important and successful systems and services in the history of the computing industry - internet, Ethernet, operating s...
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous ar...
Join IBM November 1 at 21st Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Cognitive analysis impacts today’s systems with unparalleled ability that were previously available only to manned, back-end operations. Thanks to cloud processing, IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Imagine a robot vacuum that becomes your personal assistant tha...